



Report Status: Final

017C2, AH

NL1

NL1

NL1

Patient Information	Specimen Information	Client Information
017C2, AH	Specimen: WC256489D Requisition: 0000216	Client #: 11118385 CA000159 JOSLIN LESSARD RSCH
DOB: 12/05/2020 AGE: 13M Gender: M Phone: NG Patient ID: 017C2	Collected: 01/04/2022 Received: 01/11/2022 / 14:47 EST Reported: 01/12/2022 / 13:47 EST	Attn: SARAH LESSARD 1 JOSLIN PL BOSTON, MA 02215-5306

Test Name LIPID PANEL, STANDARD	In Range	Out Of Range	Reference Range	Lab
CHOLESTEROL, TOTAL HDL CHOLESTEROL	56	199 н	<170 mg/dL >45 mg/dL	NL1 NL1
TRIGLYCERIDES		205 Н	<75 mg/dL	NL1
If a non-fasting specime repeat triglyceride test				

if clinically indicated.

Jacobson et al. J. of Clin. Lipidol. 2015;9:129-169.

LDL-CHOLESTEROL <110 mg/dL (calc) NL1 111 H LDL-C is now calculated using the Martin-Hopkins

calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C.

Martin SS et al. JAMA. 2013;310(19): 2061-2068

(http://education.QuestDiagnostics.com/faq/FAQ164) CHOL/HDLC RATIO

NON HDL CHOLESTEROL 143 H For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL

(LDL-C of <70 mg/dL) is considered a therapeutic option. GLUCOSE 107 H

Fasting reference interval

<120 mg/dL (calc)

<5.0 (calc)

65-99 mg/dL

For someone without known diabetes, a glucose value between 100 and 125 mg/dL is consistent with

prediabetes and should be confirmed with a follow-up test.

C-REACTIVE PROTEIN 5.4 <8.0 mg/L NL1 INSULIN NL1 113.6 H uIU/mL

Reference Range < or = 19.6

Risk:

Optimal < or = 19.6

Moderate NA >19.6 High

Adult cardiovascular event risk category cut points (optimal, moderate, high) are based on Quest Diagnostics population data from 12/2011.

This insulin assay shows strong cross-reactivity for some insulin analogs (lispro, aspart, and glargine) and much lower cross-reactivity with others (detemir, glulisine).

PERFORMING SITE:

NL1 QUEST DIAGNOSTICS LLC, 200 FOREST STREET 3RD FLOOR, SUITE B, MARLBOROUGH, MA 01752-3023 Laboratory Director: SALIM E KABAWAT, MD, CLIA: 22D0076229





Report Status: Final

017C2, AH

NL1

Patient Information	Specimen Information	Client Information
017C2, AH	Specimen: WC256489D Collected: 01/04/2022	Client #: 11118385
DOB: 12/05/2020 AGE: 13M Gender: M Patient ID: 017C2	Received: 01/11/2022 / 14:47 EST Reported: 01/12/2022 / 13:47 EST	

LIST OF RESULTS PRINTED IN THE OUT OF RANGE COLUMN:

 CHOLESTEROL, TOTAL
 199 H
 <170 mg/dL</th>
 NL1

 TRIGLYCERIDES
 205 H
 <75 mg/dL</th>
 NL1

If a non-fasting specimen was collected, consider repeat triglyceride testing on a fasting specimen if clinically indicated.

Jacobson et al. J. of Clin. Lipidol. 2015;9:129-169.

LDL-CHOLESTEROL 111 H <110 mg/dL (calc)

LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C.

Martin SS et al. JAMA. 2013;310(19): 2061-2068
(http://education.QuestDiagnostics.com/faq/FAQ164)

NON HDL CHOLESTEROL 143 H <120 mg/dL (calc) NL1

For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.

GLUCOSE 107 H 65-99 mg/dL NL1

Fasting reference interval

For someone without known diabetes, a glucose value between 100 and 125 $\,\mathrm{mg/dL}$ is consistent with prediabetes and should be confirmed with a follow-up test.

INSULIN 113.6 H uIU/mL NL1

Reference Range < or = 19.6

Risk:

Optimal < or = 19.6

Moderate NA High >19.6

Adult cardiovascular event risk category cut points (optimal, moderate, high) are based on Quest Diagnostics population data from 12/2011.

This insulin assay shows strong cross-reactivity for some insulin analogs (lispro, aspart, and glargine) and much lower cross-reactivity with others (detemir, glulisine).